• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾脏病及肾移植中的脂蛋白异常

Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation.

作者信息

Barbagallo Carlo Maria, Cefalù Angelo Baldassare, Giammanco Antonina, Noto Davide, Caldarella Rosalia, Ciaccio Marcello, Averna Maurizio Rocco, Nardi Emilio

机构信息

Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties-University of Palermo, Via del Vespro, 127, 90127 Palermo, Italy.

Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Section of Clinical Biochemistry, Clinical Molecular Medicine and Laboratory Medicine, University of Palermo, 90127 Palermo, Italy.

出版信息

Life (Basel). 2021 Apr 5;11(4):315. doi: 10.3390/life11040315.

DOI:10.3390/life11040315
PMID:33916487
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8067409/
Abstract

Chronic kidney disease (CKD) is one of the most important risk factors for cardiovascular disease (CVD). Despite the kidney having no direct implications for lipoproteins metabolism, advanced CKD dyslipidemia is usually present in patients with CKD, and the frequent lipid and lipoprotein alterations occurring in these patients play a role of primary importance in the development of CVD. Although hypertriglyceridemia is the main disorder, a number of lipoprotein abnormalities occur in these patients. Different enzymes pathways and proteins involved in lipoprotein metabolism are impaired in CKD. In addition, treatment of uremia may modify the expression of lipoprotein pattern as well as determine acute changes. In renal transplantation recipients, the main lipid alteration is hypercholesterolemia, while hypertriglyceridemia is less pronounced. In this review we have analyzed lipid and lipoprotein disturbances in CKD and also their relationship with progression of renal disease. Hypolipidemic treatments may also change the natural history of CVD in CKD patients and may represent important strategies in the management of CKD patients.

摘要

慢性肾脏病(CKD)是心血管疾病(CVD)最重要的危险因素之一。尽管肾脏对脂蛋白代谢没有直接影响,但晚期CKD患者通常存在血脂异常,这些患者中频繁出现的脂质和脂蛋白改变在CVD的发生发展中起着至关重要的作用。虽然高甘油三酯血症是主要病症,但这些患者还会出现多种脂蛋白异常。CKD患者中参与脂蛋白代谢的不同酶途径和蛋白质均受到损害。此外,尿毒症的治疗可能会改变脂蛋白模式的表达并导致急性变化。在肾移植受者中,主要的脂质改变是高胆固醇血症,而高甘油三酯血症则不太明显。在本综述中,我们分析了CKD患者的脂质和脂蛋白紊乱情况以及它们与肾脏疾病进展的关系。降血脂治疗也可能改变CKD患者CVD的自然病程,并且可能是CKD患者管理中的重要策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8b5/8067409/d339801fbc3b/life-11-00315-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8b5/8067409/d339801fbc3b/life-11-00315-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8b5/8067409/d339801fbc3b/life-11-00315-g001.jpg

相似文献

1
Lipoprotein Abnormalities in Chronic Kidney Disease and Renal Transplantation.慢性肾脏病及肾移植中的脂蛋白异常
Life (Basel). 2021 Apr 5;11(4):315. doi: 10.3390/life11040315.
2
Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia.肾脏病相关血脂异常中 PCSK9 和脂蛋白受体的新方面。
Cell Signal. 2019 Mar;55:53-64. doi: 10.1016/j.cellsig.2018.12.001. Epub 2018 Dec 12.
3
Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.慢性肾脏病中的血脂异常:发病机制与治疗方法
Am J Nephrol. 2008;28(6):958-73. doi: 10.1159/000144024. Epub 2008 Jul 9.
4
Dyslipidemia associated with chronic kidney disease.与慢性肾脏病相关的血脂异常
Open Cardiovasc Med J. 2011;5:41-8. doi: 10.2174/1874192401105010041. Epub 2011 Feb 24.
5
Kidney Disease in Diabetes糖尿病肾病
6
Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.脂毒性和慢性肾脏病中高密度脂蛋白介导的胆固醇逆转运受损。
J Ren Nutr. 2010 Sep;20(5 Suppl):S35-43. doi: 10.1053/j.jrn.2010.05.010.
7
New perspectives on CKD-induced dyslipidemia.慢性肾脏病相关性血脂异常的新视角。
Expert Opin Ther Targets. 2017 Oct;21(10):967-976. doi: 10.1080/14728222.2017.1369961. Epub 2017 Aug 28.
8
[Dyslipidemia and stroke in patients with chronic kidney disease].[慢性肾脏病患者的血脂异常与中风]
Acta Med Croatica. 2014 Apr;68(2):141-9.
9
The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.非高密度脂蛋白在管理5期慢性肾脏病血脂异常中的作用
Clin Nephrol. 2006 Nov;66(5):336-47. doi: 10.5414/cnp66336.
10
[Lipid metabolism abnormalities in Chronic Kidney Disease].[慢性肾脏病中的脂质代谢异常]
G Ital Nefrol. 2016;33(S68).

引用本文的文献

1
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions.降脂药物的肾脏安全性评估:介于旧有定论与新问题之间
Drugs. 2025 Mar 19. doi: 10.1007/s40265-025-02158-0.
2
Proteome of Renal Tubuli and Serum Differentiate Pre-Existing Type 2 Diabetes and Post-Transplant Diabetes in Kidney Transplant Recipients.肾小管和血清蛋白质组可区分肾移植受者中已有的2型糖尿病和移植后糖尿病。
Proteomics Clin Appl. 2025 May;19(3):e70000. doi: 10.1002/prca.70000. Epub 2025 Feb 24.
3
Dyslipidemia in Peritoneal Dialysis: Implications for Peritoneal Membrane Function and Patient Outcomes.

本文引用的文献

1
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南:通过血脂修饰降低心血管风险
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
2
Ratio of triglyceride to high-density lipoprotein cholesterol and risk of major cardiovascular events in kidney transplant recipients.肾移植受者中甘油三酯与高密度脂蛋白胆固醇的比值及主要心血管事件风险
Clin Exp Nephrol. 2019 Dec;23(12):1407-1417. doi: 10.1007/s10157-019-01776-9. Epub 2019 Aug 29.
3
Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial.
腹膜透析中的血脂异常:对腹膜功能和患者预后的影响。
Biomedicines. 2024 Oct 17;12(10):2377. doi: 10.3390/biomedicines12102377.
4
Evaluating the impact of chronic kidney disease and the triglyceride-glucose index on cardiovascular disease: mediation analysis in the NHANES.评估慢性肾脏病和甘油三酯-葡萄糖指数对心血管疾病的影响:NHANES 的中介分析。
BMC Public Health. 2024 Oct 9;24(1):2750. doi: 10.1186/s12889-024-20243-z.
5
Chronic kidney disease combined with metabolic syndrome is a non-negligible risk factor.慢性肾脏病合并代谢综合征是一个不可忽视的危险因素。
Ther Adv Endocrinol Metab. 2024 Jul 25;15:20420188241252309. doi: 10.1177/20420188241252309. eCollection 2024.
6
Coronary Atherosclerosis: Causes, Consequences, and the Passage of Time.冠状动脉粥样硬化:病因、后果及时间推移
JACC Adv. 2023 Dec 19;3(2):100756. doi: 10.1016/j.jacadv.2023.100756. eCollection 2024 Feb.
7
The Intersection of Genetic Factors, Aberrant Nutrient Metabolism and Oxidative Stress in the Progression of Cardiometabolic Disease.遗传因素、异常营养代谢与氧化应激在心脏代谢疾病进展中的交集
Antioxidants (Basel). 2024 Jan 10;13(1):87. doi: 10.3390/antiox13010087.
8
Current and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease.儿童慢性肾脏病进展风险的现有和新型生物标志物。
Nephron. 2024;148(1):1-10. doi: 10.1159/000530918. Epub 2023 May 15.
9
Atherosclerosis Specific Features in Chronic Kidney Disease (CKD).慢性肾脏病(CKD)中的动脉粥样硬化特异性特征
Biomedicines. 2022 Aug 27;10(9):2094. doi: 10.3390/biomedicines10092094.
10
Stage II of Chronic Kidney Disease-A Tipping Point in Disease Progression?慢性肾脏病的II期——疾病进展的转折点?
Biomedicines. 2022 Jun 27;10(7):1522. doi: 10.3390/biomedicines10071522.
依洛尤单抗在 FOURIER 试验中慢性肾脏病的疗效和安全性。
J Am Coll Cardiol. 2019 Jun 18;73(23):2961-2970. doi: 10.1016/j.jacc.2019.03.513.
4
Proprotein convertase subtilisin/kexin type 9 in kidney disease.蛋白酶体糜蛋白酶 9 在肾脏疾病中的作用。
Nephrol Dial Transplant. 2019 Aug 1;34(8):1266-1271. doi: 10.1093/ndt/gfz122.
5
Lipid management in patients with chronic kidney disease.慢性肾脏病患者的血脂管理。
Nat Rev Nephrol. 2018 Dec;14(12):727-749. doi: 10.1038/s41581-018-0072-9.
6
Disorders of Lipid Metabolism in Chronic Kidney Disease.慢性肾脏病中的脂代谢紊乱。
Blood Purif. 2018;46(2):144-152. doi: 10.1159/000488816. Epub 2018 Apr 27.
7
HDL in CKD-The Devil Is in the Detail.慢性肾脏病患者的高密度脂蛋白胆固醇——细节决定成败。
J Am Soc Nephrol. 2018 May;29(5):1356-1371. doi: 10.1681/ASN.2017070798. Epub 2018 Feb 22.
8
The cardiovascular risk factor profiles among end-stage renal failure patients treated with continuous ambulatory peritoneal dialysis and intermittent hemodialysis.接受持续非卧床腹膜透析和间歇性血液透析治疗的终末期肾衰竭患者的心血管危险因素概况。
Saudi J Kidney Dis Transpl. 2018 Jan-Feb;29(1):114-119. doi: 10.4103/1319-2442.225185.
9
Greater low-density lipoprotein cholesterol variability is associated with increased progression to dialysis in patients with chronic kidney disease stage 3.慢性肾脏病3期患者中,更大的低密度脂蛋白胆固醇变异性与进展至透析的风险增加相关。
Oncotarget. 2017 Dec 14;9(3):3242-3253. doi: 10.18632/oncotarget.23228. eCollection 2018 Jan 9.
10
The role of lipoprotein (a) in chronic kidney disease.脂蛋白(a)在慢性肾脏病中的作用。
J Lipid Res. 2018 Apr;59(4):577-585. doi: 10.1194/jlr.R083626. Epub 2018 Jan 29.